T cells in patients undergoing chronic hemodialysis: mitogenic response, suppressor activity, and interleukin-2 production and receptor generation.
The functional response of peripheral blood T lymphocytes was studied in patients with end-stage renal disease treated by chronic hemodialysis for over 1 year. Proliferation after phytohemagglutinin stimulation of patients' peripheral blood mononuclear cells and of T lymphocyte fractions isolated by either sheep erythrocyte rosetting or by use of a nylon wool column was significantly reduced as compared with that of corresponding fractions from healthy control subjects (P less than 0.001). The induction of suppressor cell activity by concanavalin A in rosetted T cell fractions was higher with cells of hemodialyzed patients than with control cells (P less than 0.025). The expression of class II MHC antigen (HLA-DR) by the T8 lymphocyte subset after concanavalin A induction, as determined by staining with monoclonal antibodies and two-color fluorescence analysis by flow cytometry, was also higher in hemodialyzed subjects (P less than 0.025). Since contamination by non-T cells in such cell fractions and increases in proliferation after indomethacin treatment of peripheral blood mononuclear cells were similar in hemodialyzed and control subjects, it is unlikely that the depressed T lymphocyte responses and the increased suppressor cell activity can be attributed to increased peripheral blood monocyte counts observed in patients undergoing hemodialysis. Studies of the biological events associated with the activation of lymphocytes of hemodialyzed patients revealed a reduction in expression of interleukin 2 receptor in the plasma membrane of phytohemagglutinin-stimulated lymphocytes as determined by staining with monoclonal antibody (P less than 0.01). In addition, a very low secretion of interleukin 2 by stimulated peripheral blood mononuclear cell populations was observed in about one-half of patients receiving hemodialysis.
D000328:Adult; D000368:Aged; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis*; D007676:Kidney Failure, Chronic / Q000276:immunology* / Q000628:therapy; D008213:Lymphocyte Activation; D008875:Middle Aged; D010835:Phytohemagglutinins; D011971:Receptors, Immunologic / Q000096:biosynthesis*; D015375:Receptors, Interleukin-2; D012016:Reference Values; D006435:Renal Dialysis; D013601:T-Lymphocytes / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
D007376:Interleukin-2; D010835:Phytohemagglutinins; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2